LTR Pharma secures exclusive US ROXUS partnership

LTR Pharma (ASX:LTP) has taken a leap towards entering the world’s largest erectile dysfunction market by executing a binding term sheet with Strive Specialities.

Under the arrangement, Strive Pharmacy will serve as the exclusive United States pharmacy fulfilment partner for ROXUS, the company's proprietary, rapid-acting intranasal treatment.

As the designated product owner, intellectual property holder, and formulation supplier, LTR Pharma will leverage Strive’s multi-state 503A personalised medicine platform to anchor its national dispensing infrastructure.

The commercial alignment provides LTR Pharma with immediate, scalable access to extensive US healthcare provider and clinic networks, expanding future patient access opportunities while reducing operational launch execution risks.

By incorporating a robust multi-channel commercialisation strategy that integrates telehealth platforms, direct-to-consumer pharmacy fulfilment, and established provider networks, ROXUS is positioned to disrupt traditional market dynamics.

The product's innovative intranasal delivery mechanism bypasses the standard oral PDE5 inhibitor pathway, catering directly to the growing consumer demand for on-demand, fast-acting treatment options.